

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.


What is claimed is:

1.(Previously presented.) A compound in accord with formula I:



enantiomers and pharmaceutically-acceptable salts thereof, wherein:

Q is a moiety of formula II



E is selected from thiazolyl, imidazolyl, and

D is selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, phenyl, phenylsulphonyl or pyridyl, wherein D may have 1, 2 or 3 substituents selected from halogen, alkoxy or trifluoromethyl.

2.(Currently amended.) A compound according to Claim 1, wherein:

D is selected from hydrogen, bromine, n-pentyl, phenyl, biphenyl, phenylsulphonyl or pyrid-2-yl, wherein D may have 1, 2 or 3 substituents selected from halogen, alkoxy or trifluoromethyl.

3.(Currently amended.) A compound selected from:

4-(2-bromo-thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane;

4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane having;

4-(2-phenyl-thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane;

4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane;

4-(thiazol-2-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane;

4-(2-phenyl-thiazol-4-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; and

4-(4-(3-bromo-phenyl)thiazol-2-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane;

4-(4-phenyl-thiazol-2-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane, and

2 of 4

~~4-(4-(biphen-3-yl)thiazol-2-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane.~~

4-10.(Canceled.)

11.(original) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically-acceptable diluent or carrier.

12-15. (Canceled.)